Basel-based Atlas Bio has raised $12.5M led by Creandum to use AI to simulate Phase II drug trials. First trial results are expected in about six weeks ...

Swiss startup Atlas Bio raises $12.5M to build in silico clinical trials and tackle the 70% Phase II failure rate. What is ...

The Swiss startup is developing an AI foundation model that predicts drug efficacy and safety in virtual patients, ...

First-in-human study evaluates Strand’s ability to unlock the potential of systemic mRNA-encoded medicines with an IL-12 ...

Climb Bio, Inc. announced initial PrisMN Phase 2 data for budoprutug, its anti-CD19 monoclonal antibody, in primary membranous nephropathy (“pMN”). PrisMN is an ongoing Phase 2 dose-escalation trial ...

Boost ROI with AI-enabled automation, advanced assays, integrated data systems and global partnerships that accelerate compliant drug development.Dublin, Oct. (GLOBE NEWSWIRE) -- "Bioanalytical ...

A novel lytic phage isolated from hospital sewage reduced viable drug-resistant Klebsiella pneumoniae in catheter biofilms by ...

Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, ...

Bio-Techne's shares have gained 10.1% over the past year, underperforming the broader S&P 500 Index ($SPX), which advanced 13.4% over the same period. In fact, the stock has also underperformed its ...

BIO-key International Inc. stocks have been trading up by 12.61 percent amid strong investor optimism over its latest ...

ZURICH, Oct 27 (Reuters) - Swiss AI start-up Atlast Bio, which runs drug trials on virtual patients, has received $12.5 million in funding led by Swedish venture capital firm Creandum, an early backer ...